NCT04710628View on ClinicalTrials.gov

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

January 31, 2026

Conditions
Metastatic Thymic CarcinomaThymoma Type B3
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.

DRUG

Lenvatinib 10 mg

Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)

Trial Locations (13)

Unknown

Institut Bergonié, Bordeaux

Centre Oscar Lambert, Lille

Hôpitaux Universitaires de Marseille - Hôpital Nord, Marseille

Institut Curie, Paris

Centre Hospitalier Universitaire de Toulouse, Toulouse

IGR Gustave Roussy, Villejuif

A.O.U. San Luigi Gonzaga, Orbassano

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña

Hospital Sant Creu i Sant Pau, Barcelona

Hospital Universitario La Paz, Madrid

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitari i Politècnic La Fe, Valencia

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

MedSIR

OTHER